CASP4 and pneumonia: Our findings collectively suggest that targeting the CASP11 homolog, human CASP4, during COVID-19 will prevent severe pneumonia, inflammation, tissue damage, and thrombosis as well as accompanying repercussions such as low oxygen, lung failure, need for ventilators, and possibly long-term sequelae.